Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: RBD-specific memory B cells expand in naive and recovered subjects following mRNA vaccination (A) Study design of the Emory SARS-CoV-2 convalescence and vaccination cohort. Frequency of RBD-specific memory B cells (MBCs) in subjects for 1–12 months following confirmed SARS-CoV-2 infection, reported as the percentage of total CD19 + cells. The final visit before vaccination is shown in blue (Pfizer) or red (Moderna). (B) Gating scheme of RBD-specific MBCs, pre-gated as live single CD19 + IgD − CD20 + cells, in a naive (top) and recovered (bottom) donor before vaccination (left) and after dose 2 (right). (C) RBD-specific MBCs as the percentage of CD19 + for individual vaccinated donors by days post-dose 1 and 2. (D) RBD-specific MBCs as the percentage of CD19 + by time point. (E) RBD-specific MBCs shown for naive (gray, open circles) and recovered (black, closed circles) for 1–6 months following full vaccination. Coefficient of determination (r 2 ) and significance are determined from linear regression analysis. ∗∗∗p < 0.001. (F) Gating scheme of RBD-specific IgG (left) or IgA (right) expressing MBCs, shown for a recovered subject post-dose 2. (G) RBD-specific IgG+ (left) or IgA+ (right) MBCs as percentage of CD19 + by time point. (A–G) Blue = Pfizer vaccination (recovered n = 18, naive n = 18), red = Moderna (recovered n = 13, naive n = 9), tested in singlets. Open circles are naive subjects, and closed circles are recovered subjects. (D and F) Values are medians ±95% confidence interval (CI). Statistics were calculated using mixed-effects model with Geisser-Greenhouse correction. Blue values indicate Pfizer, red values indicate Moderna, as comparisons with time point 1. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Infection, Expressing

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: RBD-specific MBCs upregulate CD71 following infection and vaccination (A) Gating scheme for CD71 expression on non-RBD binding (left) and RBD-binding (right) MBCs. (B) CD71 expression as the percentage of parent is quantified in RBD-binding (triangles) and non-RBD-binding (circles) following SARS-CoV-2 infection (top) or vaccination of recovered (middle) and naive (bottom) subjects. Blue = Pfizer vaccination (recovered n = 18, naive n = 18), red = Moderna (recovered n = 13, naive n = 9), tested in singlets. Open symbols are naive subjects, and closed symbols are recovered subjects. Statistics were calculated using mixed-effects model with Geisser-Greenhouse correction. ∗p < 0.05, ∗∗∗∗p < 0.0001.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Infection, Expressing, Binding Assay

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: Plasmablast responses in naive and recovered individuals post-SARS-CoV-2 mRNA vaccination (A) Gating scheme of plasmablasts by CD20 and CD38, pre-gated as CD19 + IgD − , in a representative naive post-dose 2 (top) or recovered post-dose 1 (bottom). (B) Plasmablasts as the percentage of CD19 for individual vaccinated donors by days post-dose 1 and 2. (C) Plasmablasts as the percentage of CD19 + by time point in naive (left) and recovered (right) vaccinees. (D) Gating scheme of RBD-specific plasmablasts pre- and post-vaccination in a naive subject. (E) RBD-specific total (left), IgG+ (middle), and IgA+ (right) as the percentage of plasmablasts by time point in naive (top) and recovered (bottom) vaccinees. (A–F) Blue = Pfizer vaccination (recovered n = 18, naive n = 18), red = Moderna (recovered n = 13, naive n = 9), tested in singlets. Open circles are naive subjects, closed circles are recovered. (C and F) Statistics were calculated using mixed-effects model with Geisser-Greenhouse correction. Blue values indicate Pfizer, red values indicate Moderna, as comparisons with time point 1. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques:

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: Recovered individuals generate faster and more robust antibody responses to mRNA vaccination against SARS-CoV-2 than naive individuals (A) IgG and IgA NTD-, RBD-, and S-specific binding titers over the course of vaccination in recovered (Pfizer = 18, Moderna = 10) and naive (Pfizer = 18, Moderna = 9) individuals as determined by MSD-ELICA calculated from reference standard curve. (B) IgG binding and neutralizing titers against WT, Beta, and Delta RBDs in recovered (Pfizer n = 12, Moderna n = 11) and naive individuals (Pfizer n = 6, Moderna n = 6) at 1-month post-vaccination as determined by MSD-ELICA and in vivo neutralization. (C) Neutralization titers in recovered (1-month post-infection [n = 39], 1-month post-vaccination [n = 39], 6-month post vaccination [n = 37]) and naive (1-month post-vaccination [n = 27], 6-month post vaccination [n = 25]) individuals against SARS-CoV-2 WT, Beta, or Delta variants. The 6-month data for the WT virus was previously published in Edara et al. and is shown here for comparative reasons only. MSD-ELICA and neutralization assays were run in duplicate. Significance was determined using either as differences from baseline (T1) using mixed-effects model with Geisser-Greenhouse correction and Tukey’s multiple comparison test or using (1) Brown-Forsythe ANOVA and Dunnet’s T3 multiple comparison test and (2) two-way ANOVA with Geisser-Greenhouse correction. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Binding Assay, In Vivo, Neutralization, Infection

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: Antigen-specific MBCs and serological responses to SARS-CoV-2 infection correlate with responses to mRNA vaccination (A) RBD- and S-titers correlate with neutralizing titers 1-month post-infection (left) and 1-month post-vaccination in recovered (middle) and naive (right). (B) RBD + MBCs (percentage of CD19 + ) correlated with RBD-specific IgG titers (left) and 1-month post-vaccination in recovered (middle) and naive (right). (C) RBD- and S-binding titers, neutralizing titers, and RBD + MBCs (percentage of CD19 + ) correlated between 1-month post-infection and 1-month post-vaccination (top) and 1-month pre-vaccination and 1-month post-vaccination (bottom). (D) RBD-binding B cells post-infection (top) and pre-vaccination (bottom) are correlated with RBD-specific IgG following vaccination. Coefficient of determination (r 2 ) and significance determined from linear regression analysis.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Infection, Binding Assay

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: Naive Moderna-vaccinated individuals retain greater neutralizing capacity after depletion of RBD-specific fraction of plasma (A) MSD-ELICA calculated titers for RBD-specific IgM, IgG, and IgA before (pre) and after (post) RBD depletion (left) and the percentage reduction of RBD-specific IgG post-RBD depletion as calculated from fold change (right). (B) Neutralization titers against SARS-CoV-2 WT pre- and post-RBD depletion. (C and D) The percentage reduction of neutralization post RBD-depletion as calculated from fold change. (E) IgG titers against RBD (WT, Beta, Delta) and neutralization titers (WT, Beta, Delta) correlated the percentage reduction of neutralization post RBD-depletion; coefficient of determination (r 2 ) and significance determined from linear regression analysis. Blue = Pfizer vaccination (recovered n = 12, naive n = 6), red = Moderna (recovered n = 11, naive n = 6), tested in duplicate. Open circles are naive subjects, closed circles are recovered. Statistics were calculated by Brown-Forsythe ANOVA and Dunnet’s T3 multiple comparisons (A–D). ∗p < 0.05

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Neutralization

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet: Naive vaccinees exhibit a faster decline in S-, RBD-, and NTD-specific IgG 6 months after vaccination than previously SARS-CoV-2 infected vaccinees S-specific IgG (left), RBD-specific IgG (middle), and NTD-specific IgG (right) are shown for naive (green, open circles) and recovered (black, closed circles) subjects for 1–6 months following full vaccination. Best-fit lines determined using an exponential decay model and antibody half-lives (t 1/2 ) calculated.

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Infection

Journal: Cell Reports Medicine

Article Title: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination

doi: 10.1016/j.xcrm.2022.100603

Figure Lengend Snippet:

Article Snippet: V-PLEX SARS-CoV-2 Panel 11 (IgG) Kit , Mesoscale Discovery , K15455U.

Techniques: Recombinant, Lysis, Labeling, Software